Gilead Response: Two Clinical Trials are being conducted in Wuhan to evaluate the effectiveness of Redcyway

On the evening of February 5, Gilead Sciences responded to the progress of clinical trials of The New Coronary pneumonia, a potentially effective drug, Redsiewe, which is most concerned by the public. In an email to the media, Gilead said Gilead had reached an agreement with the Chinese health authorities to support two clinical trials of people infected with 2019-nCoV to determine the safety and effectiveness of Remdesivir as a potential treatment for coronavirus.

One study assessed the therapeutic effectiveness of Remdesivir for patients who were diagnosed with infection 2019-nCoV and were hospitalized but did not exhibit significant clinical symptoms (e.g., additional oxygen absorption) and another assessed Remdesivir for more severe clinical symptoms (e.g., oxygen absorption required). the efficacy of the confirmed patient.

Both clinical trials, led by Chinese researchers, are conducted in Wuhan. Gilead provides the drugs needed for the research free of charge and supports the design and development of the research.

Remdesivir is a broad-spectrum antiviral drug under development that has not yet been approved in any country around the world. Remdesivir has demonstrated the activity of MERS and SARS virus pathogens in in vitro and in vitro animal models, and they are also coronaviruses, structurally similar to 2019-nCoV. Limited preclinical data for MERS and SARS indicate that Remdesivir may have potential lyno activity for 2019-nCoV.

Gilead expects the lead researchers in clinical trials to release more details in the near future.

The company also notes that Remdesivir is an experimental drug that has so far been used by only a very small number of patients infected with 2019-nCov, so we do not know enough about its efficacy and are not currently sufficient to ensure that the drug is widely available. If the results of the preliminary study show the potential safety and efficacy of Remdesivir’s treatment of 2019-nCoV infections, we will endeavour to develop programmes to make Remdesivir, an experimental drug, available to more patients through appropriate channels. We are also in discussions with a number of agencies about the possibility of future clinical trials.

On the production supply side, Gilead also said that in response to the Ebola outbreak in West Africa in recent years, Gilead expanded Remdesivir’s production, established a stock of products to cope with future disease epidemics, and increased the stock of raw materials used to make Remdesivir. The company is using this inventory to meet the demand for “sympathetic drugs” and the demand for two clinical trials currently planned for China.

“While it has not yet been determined whether the drug can safely and effectively treat 2019-nCoV infections, given the urgency of the current situation, we are taking a number of measures to accelerate production progress and increase supply, including expanding the network of external pharmaceutical partners to accelerate the procurement of raw materials, API and pharmaceutical production; We started manufacturing Remdesivir in-house to complement the capacity of our external production network. Gilead said.